FTO及其抑制剂在恶性肿瘤中的研究进展  

Advances in the study of FTO and its inhibitors in malignant tumors

作　　者：张静[1,2] 谷保红 朱竞雨 许博 何普毅 蒲唯高 王琛[1] 陈昊[1,2,3] Zhang Jing;Gu Baohong;Zhu Jingyu;Xu Bo;He Puyi;Pu Weigao;Wang Chen;Chen Hao(The Second Clinical Medical School,Lanzhou University,Lanzhou 730030,China;Key Laboratory of Digestive System Oncology,The Second Hospital of Lanzhou University,Lanzhou 730030,China;Department of Oncology Surgery,The Second Hospital of Lanzhou University,Lanzhou 730030,China)

机构地区：[1]兰州大学第二临床医学院,甘肃兰州730030 [2]兰州大学第二医院消化系统肿瘤重点实验室,甘肃兰州730030 [3]兰州大学第二医院肿瘤外科,甘肃兰州730030

出　　处：《兰州大学学报（医学版）》2023年第4期89-94,共6页Journal of Lanzhou University（Medical Sciences）

基　　金：国家自然科学基金资助项目(82160129);甘肃省重点人才资助项目(2019RCXM020);甘肃省科技重大专项资助项目(19Z D2WA001);兰州大学第二医院“萃英科技创新”计划资助项目(CY2017-ZD01);兰州大学第二医院“萃英学子科研培育”计划资助项目(CYXZ2020-07)。

摘　　要：N^(6)-甲基腺苷(N^(6)-methyladenosine,m^(6)A)是RNA最常见的内部修饰,在RNA的加工、转运、翻译及稳定性方面发挥重要作用。脂肪量和肥胖相关基因(fat mass and obesity-associated,FTO)作为第一个被发现的mRNA m^(6)A去甲基化酶,参与多种肿瘤的发生、发展及治疗抵抗,调节肿瘤干细胞自我更新、肿瘤代谢及肿瘤微环境。作为肿瘤治疗有希望的靶点,越来越多的FTO抑制剂被研发出来并在临床前研究中取得了良好的治疗效果。本研究就FTO在肿瘤发生、肿瘤干细胞自我更新、肿瘤免疫和代谢及治疗抵抗等方面的功能和潜在分子机制的研究进展作一综述,并讨论靶向FTO在肿瘤治疗中的应用前景。N^(6)-methyladenosine(m^(6)A)is the most common internal modification of RNA,playing an important role in RNA processing,transport,translation and stability.Fat mass and obesity-associated(FTO),the first identified mRNA m^(6)A demethylase,is involved in the genesis,development and therapeutic resistance of many tumors,regulating tumor stem cell's self-renewal,tumor metabolism and the tumor microenvironment.As a promising target for tumour therapy,more and more FTO inhibitors are being developed and have achieved good therapeutic effects in preclinical studies.In this paper,we reviewed the functional and potential molecular mechanisms of FTO in tumorigenesis,tumor stem cell's self-renewal,tumor immunity and metabolism,and therapeutic resistance,and discussed the prospects of targeting FTO in tumor therapy.

关 键 词：脂肪量和肥胖相关基因 肿瘤 N^(6)-甲基腺苷 抑制剂 

分 类 号：R730.5[医药卫生—肿瘤]